158 related articles for article (PubMed ID: 24425702)
1. Informed choice of composite end points in cardiovascular trials.
Gómez G; Gómez-Mateu M; Dafni U
Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):170-8. PubMed ID: 24425702
[TBL] [Abstract][Full Text] [Related]
2. Temporal Trends in Use of Composite End Points in Major Cardiovascular Randomized Clinical Trials in Prominent Medical Journals.
Tan NS; Ali SH; Lebovic G; Mamdani M; Laupacis A; Yan AT
Circ Cardiovasc Qual Outcomes; 2017 Oct; 10(10):. PubMed ID: 28954803
[TBL] [Abstract][Full Text] [Related]
3. Contribution of individual components to composite end points in contemporary cardiovascular randomized controlled trials.
Shaikh A; Ochani RK; Khan MS; Riaz H; Khan SU; Sreenivasan J; Mookadam F; Doukky R; Butler J; Michos ED; Kalra A; Krasuski RA
Am Heart J; 2020 Dec; 230():71-81. PubMed ID: 32941789
[TBL] [Abstract][Full Text] [Related]
4. Statistical considerations when using a composite endpoint for comparing treatment groups.
Gómez G; Lagakos SW
Stat Med; 2013 Feb; 32(5):719-38. PubMed ID: 22855368
[TBL] [Abstract][Full Text] [Related]
5. The problem with composite end points in cardiovascular studies: the story of major adverse cardiac events and percutaneous coronary intervention.
Kip KE; Hollabaugh K; Marroquin OC; Williams DO
J Am Coll Cardiol; 2008 Feb; 51(7):701-7. PubMed ID: 18279733
[TBL] [Abstract][Full Text] [Related]
6. Shift from surrogate end point to outcome trials: implications for cardiovascular safety assessment in development programs for antidiabetic drugs.
Marcinak JF; Viswanathan P; Arora V; Roebel LE; Strack TR; Leifke E
Clin Pharmacol Ther; 2012 Mar; 91(3):514-20. PubMed ID: 22113235
[TBL] [Abstract][Full Text] [Related]
7. Selecting the primary endpoint in a randomized clinical trial: The ARE method.
Plana-Ripoll O; Gómez G
J Biopharm Stat; 2016; 26(5):880-98. PubMed ID: 26400217
[TBL] [Abstract][Full Text] [Related]
8. Determining the most appropriate components for a composite clinical trial outcome.
Bethel MA; Holman R; Haffner SM; Califf RM; Huntsman-Labed A; Hua TA; McMurray J
Am Heart J; 2008 Oct; 156(4):633-40. PubMed ID: 18926145
[TBL] [Abstract][Full Text] [Related]
9. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET).
Kappert K; Böhm M; Schmieder R; Schumacher H; Teo K; Yusuf S; Sleight P; Unger T;
Circulation; 2012 Aug; 126(8):934-41. PubMed ID: 22829023
[TBL] [Abstract][Full Text] [Related]
10. Key issues in end point selection for heart failure trials: composite end points.
Neaton JD; Gray G; Zuckerman BD; Konstam MA
J Card Fail; 2005 Oct; 11(8):567-75. PubMed ID: 16230258
[TBL] [Abstract][Full Text] [Related]
11. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials.
Ferreira-González I; Busse JW; Heels-Ansdell D; Montori VM; Akl EA; Bryant DM; Alonso-Coello P; Alonso J; Worster A; Upadhye S; Jaeschke R; Schünemann HJ; Permanyer-Miralda G; Pacheco-Huergo V; Domingo-Salvany A; Wu P; Mills EJ; Guyatt GH
BMJ; 2007 Apr; 334(7597):786. PubMed ID: 17403713
[TBL] [Abstract][Full Text] [Related]
12. A simple adaptation method improved the interpretability of prediction models for composite end points.
Gondrie MJ; Janssen KJ; Moons KG; van der Graaf Y
J Clin Epidemiol; 2012 Sep; 65(9):946-53. PubMed ID: 22658619
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of percutaneous coronary intervention with stenting and coronary artery bypass surgery for multivessel coronary artery disease: a meta-analysis with 5-year patient-level data from the ARTS, ERACI-II, MASS-II, and SoS trials.
Daemen J; Boersma E; Flather M; Booth J; Stables R; Rodriguez A; Rodriguez-Granillo G; Hueb WA; Lemos PA; Serruys PW
Circulation; 2008 Sep; 118(11):1146-54. PubMed ID: 18725490
[TBL] [Abstract][Full Text] [Related]
14. Selection of composite binary endpoints in clinical trials.
Bofill Roig M; Gómez Melis G
Biom J; 2018 Mar; 60(2):246-261. PubMed ID: 29023990
[TBL] [Abstract][Full Text] [Related]
15. Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials.
Bakal JA; Westerhout CM; Armstrong PW
Stat Methods Med Res; 2015 Dec; 24(6):980-8. PubMed ID: 22275378
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular safety of varenicline: patient-level meta-analysis of randomized, blinded, placebo-controlled trials.
Ware JH; Vetrovec GW; Miller AB; Van Tosh A; Gaffney M; Yunis C; Arteaga C; Borer JS
Am J Ther; 2013; 20(3):235-46. PubMed ID: 23615317
[TBL] [Abstract][Full Text] [Related]
17. Surrogate end points in secondary analyses of cardiovascular trials.
Buhr KA
Prog Cardiovasc Dis; 2012; 54(4):343-50. PubMed ID: 22226002
[TBL] [Abstract][Full Text] [Related]
18. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
[TBL] [Abstract][Full Text] [Related]
19. [Controlled randomized clinical trials].
Jaillon P
Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
Knopp RH; d'Emden M; Smilde JG; Pocock SJ
Diabetes Care; 2006 Jul; 29(7):1478-85. PubMed ID: 16801565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
